Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Via Dialysate and IV to Pediatric Patients on Chronic Hemodialysis

Trial Profile

Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Via Dialysate and IV to Pediatric Patients on Chronic Hemodialysis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Ferric pyrophosphate (Primary)
  • Indications Iron deficiency anaemia
  • Focus Pharmacokinetics
  • Sponsors Rockwell Medical Technologies
  • Most Recent Events

    • 30 Oct 2017 According to a Rockwell Medical India media release, data from the study will be presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting.
    • 18 Jan 2017 Status changed from recruiting to completed.
    • 11 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top